Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

MDAT

From Wikipedia, the free encyclopedia
MDAT
Clinical data
Other names6,7-MDAT; 6,7-Methylenedioxy-2-aminotetralin
Drug classSerotonin releasing agent; Entactogen
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H13NO2
Molar mass191.230 g·mol−1
3D model (JSmol)
  • C3Cc1cc2OCOc2cc1CC3N

MDAT, also known as 6,7-methylenedioxy-2-aminotetralin, is a drug of the 2-aminotetralin family developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.

See also

[edit]

References

[edit]
  1. 1 2 Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=MDAT&oldid=1341021704"